What's Happening?
Avenzo Therapeutics, a clinical-stage biotechnology company focused on developing next-generation oncology therapies, has announced the appointment of Scott Lipman as its new Chief Financial Officer. Lipman,
who will continue to serve as the company's Chief Business Officer, succeeds Paolo Tombesi following his retirement. Athena Countouriotis, Co-founder, President, and CEO of Avenzo, praised Lipman's integral role in driving business development and financing efforts, which have helped build a portfolio of four potential best-in-class oncology assets. Lipman joined Avenzo in March 2023 and was promoted to Chief Business Officer in November 2024. His previous experience includes leadership roles at Turning Point Therapeutics and Healthcare Investment Banking at Goldman Sachs. Lipman holds a B.S. in Chemical Engineering from UCLA and an M.B.A. from Northwestern University.
Why It's Important?
The appointment of Scott Lipman as Chief Financial Officer is a strategic move for Avenzo Therapeutics as it seeks to advance its clinical-stage oncology programs and support the company's next stage of growth. Lipman's extensive experience in business development and finance, particularly in the biotechnology sector, positions him to effectively drive Avenzo's strategic and financial objectives. His leadership is expected to enhance the company's ability to develop innovative oncology therapies, potentially impacting the biotechnology industry by introducing new treatments for advanced solid tumors and HR+/HER2- metastatic breast cancer. This appointment underscores Avenzo's commitment to strengthening its leadership team to achieve its long-term goals.
What's Next?
With Scott Lipman at the helm of financial operations, Avenzo Therapeutics is poised to continue advancing its pipeline of oncology therapies. The company is currently studying several drug candidates in Phase 1 and Phase 2 trials, including AVZO-021 and AVZO-023, which target key enzymes involved in cell cycle regulation. Additionally, Avenzo is developing antibody-drug conjugates (ADCs) such as AVZO-1418 and AVZO-103 for the treatment of advanced solid tumors. Lipman's leadership is expected to facilitate the progression of these clinical trials and support the company's strategic priorities, potentially leading to new treatment options for cancer patients.
